Biospecimen Core/Immunologic Monitoring and Cellular Products Laboratory

生物样本核心/免疫监测和细胞产品实验室

• 批准号: 9091456
• 负责人: Lisa Helene Butterfield
• 金额: $ 40.63万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-26 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9091456
• 关键词: Aftercare; Antibody Response; Antigens; Autologous; Autologous Dendritic Cells; Biological Assay; Biological Markers; Biostatistics Core; Blood; Blood Banks; Blood Vessels; C-reactive protein; CD14 gene; CD3 Antigens; CD4 Positive T Lymphocytes; CD8 Antigens; CD8B1 gene; CTAG1 gene; CXCL10 gene; CXCL11 gene; CXCL3 gene; CXCL9 gene; Cells; Clinical; Clinical Protocols; Clinical Trials; Communities; Cyclic GMP; Data; Dendritic Cell Vaccine; Eastern Cooperative Oncology Group; Effector Cell; Equipment and supply inventories; Flow Cytometry; Growth; HLA-DR Antigens; Helper-Inducer T-Lymphocyte; IL2RA gene; IL8 gene; ITGAM gene; Immune response; Immunity; Immunologic Monitoring; Infiltration; Informatics; Interferon Alfa-2b; Interferon Type II; Interleukin-1 alpha; Interleukin-10; Interleukin-17; Interleukin-2; Interleukin-6; Laboratories; Leukapheresis; Link; Lymphoid; Monophenol Monooxygenase; Myelogenous; NK Cell Activation; Natural Killer Cells; Outcome; Patients; Peptides; Peripheral Blood Mononuclear Cell; Process; Production; Protocols documentation; Regulatory T-Lymphocyte; Research; SILV gene; Sampling; Serum; Site; Skin Cancer; Suppressor-Effector T-Lymphocytes; T cell response; T-Lymphocyte; TNF gene; Testing; Time; Tissue Banking; Tissue Banks; Vaccine Antigen; Vascular Endothelial Growth Factors; chemokine; cytokine; enzyme linked immunospot assay; melanoma; monocyte; programs; response; tumor

Core B serves the MSCP SPORE as the Biospecimen Core, as well as the Immunologic Monitoring and Cellular Products Laboratory (IMCPL). The laboratory supports the SPORE community with blood and tissue banking for patients submitting blood and/or tumor to the Melanoma Program tissue bank (#96-099), as well as ciinicai protocol-specific banking. For all of the projects proposed in this renewal, the Core wiil perform a wide variety of standardized, SOP-driven immunological monitoring assays. For Project 2, Core B will also prepare autologous dendritic cell vaccines. Core B will support each Project as follows: Project 1 (Tarhini/Storkus) Core B will support Project 1 Aims 1a and lb, testing circulating cellular and serum biomarkers from the trial ECOG 1609. Core B will assess host effector and suppressor cellular immune responses. We will perform multicolor flow cytometry to compare PBMC before and after treatment, focusing on circulating suppressor cells (Treg and MDSC) and antigen-specific effector and helper T cells, as well as serum biomarkers. Project 2 (Butterfield/Kirkwood): The Core will support Aim 1 (clinical trial #09-021) with autologous AdVTMM2-transduced dendritic cell vaccine manufacture, characterization and release for therapy. The Core will process all blood, leukapheresis and tumor samples and perform all banking For Aim 2, The Core will perform many standardized immune response assays. Project 3 (Zarour/Ferrone): The Core will support this Project with banking of PBMC and testing for activation and expansion of shared melanoma antigen-specific T cells. Project 4 (Falo/Geskin/Tawbi) Core B will perform the systemic immunologic monitoring proposed in Project 4 for both CTCL and melanoma patients. This will include serum, PBMC and tumor sample banking and testing, including innate and effector cell analysis. Together, the Biospecimen Core B will support the projects of the SPORE with tissue banking (all Projects), standardized immunologic monitoring (all Projects) and cGMP cellular product production for therapy (Project 2). Data generated in Core B will be analyzed in Biostatistics Core C and correlated to clinical parameters. The blood and tissue bank data and inventory are linked to the Clinical Trials Management Application and and will be part of the Research Data Warehouse developed by and managed in Informatics Core D.

核心B将MSCP孢子作为生物晶体核心，以及免疫监测和细胞产品实验室（IMCPL）。该实验室为孢子群落提供血液和组织库，用于将血液和/或肿瘤提交黑色素瘤计划组织库（＃96-099）以及特定于Ciinicai方案的患者。对于此续签中提出的所有项目，核心将执行各种标准化，SOP驱动的免疫学监测测定法。对于项目2，核心B还将准备自体树突状细胞疫苗。 核心B将支持每个项目如下：项目1（Tarhini/Storkus）核心B将支持项目1 AIMS 1A和LB，测试试验ECOG 1609的循环细胞和血清生物标志物。核心B将评估宿主效应子和抑制器抑制器细胞免疫反应。我们将执行多色流式细胞术以比较处理前后的PBMC，重点是循环抑制细胞（Treg和MDSC），抗原特异性效应子和辅助T细胞以及血清生物标志物。项目2（Butterfield/Kirkwood）：核心将支持AIM 1（临床试验＃09-021），并具有自体advtmm2转移的树突状细胞疫苗制造，表征和释放用于治疗。核心将处理所有血液，白细胞术和肿瘤样本，并为AIM 2执行所有银行业务，核心将执行许多标准化的免疫反应测定。项目3（Zarour/ferrone）：核心将通过BANT PBMC的库来支持该项目，并测试共享黑色素瘤抗原特异性T细胞的激活和扩展。项目4（falo/geskin/tawbi）核心B将针对CTCL和黑色素瘤患者进行项目4中提出的系统性免疫监测。这将包括血清，PBMC和肿瘤样品库和测试，包括先天和效应细胞分析。 共同核心B一起将通过组织库（所有项目），标准化免疫监测（所有项目）和CGMP蜂窝产品生产用于治疗（项目2），以支持孢子的项目（所有项目）。核心B中产生的数据将在生物统计学核心C中进行分析，并与临床参数相关。血液和组织库数据和库存与临床试验管理应用程序有关，并将成为Informatics Core核心D的研究数据仓库的一部分。